Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Chin J Cancer Res. 2013 Oct;25(5):505-13. doi: 10.3978/j.issn.1000-9604.2013.08.14.
To investigate the synergistic inhibitory effects of wogonin (WOG) and chemotherapeutic drugs on growth of gastric cancer cells and tumor xenografts.
The IC50 values of WOG, cisplatin (CDDP) and paclitaxel (PTX) in four gastric cancer cell lines were determined by MTS assay. Hoechst staining and the median effect method of Chou-Talalay were used to assess the apoptosis of cells and the interaction of two drugs, respectively. BGC-823-derived xenografts in nude mice were established to investigate the effects of WOG combined with chemotherapeutic drugs in vivo.
WOG, CDDP and PTX inhibited the growth of BGC-823, MGC-803, MKN-45 and HGC-27 gastric cancer cells in a dose-dependent manner. WOG combined with CDDP or PTX synergistically inhibited the growth of all gastric cancer cell lines in vitro. In BGC-823, MGC-803, HGC-27 and MKN-45 cell lines, synergisms between WOG and PTX were shown when the fraction affected (Fa) values were <0.45, <0.90, <0.85 and <0.60. While WOG and CDDP had a synergistic inhibitory effect when the Fa values were >0, >0, >0.65 and >0.10. From the results of in vivo experiments using tumor xenografts, WOG and low-dose PTX showed better efficacy than either drug alone. The inhibitory percentages of tumor weight were 61.58%, 20.29%, and 22.28% for the combination, WOG-alone, and low-dose PTX-alone groups, respectively. Notably, WOG combined with CDDP displayed very high toxicity.
A synergistic inhibitory effect on growth was observed when WOG was combined with low-dose PTX in gastric cancer cells and tumor xenografts. These findings provide evidence for the design of a clinical trial to test the combination of WOG with low-dose PTX in human gastric cancer.
研究汉黄芩素(WOG)与化疗药物联合抑制胃癌细胞生长及肿瘤异种移植的协同作用。
采用 MTS 法测定 WOG、顺铂(CDDP)和紫杉醇(PTX)在四种胃癌细胞系中的 IC50 值。采用 Hoechst 染色和 Chou-Talalay 中值效应法分别评估细胞凋亡和两种药物的相互作用。建立裸鼠 BGC-823 来源的异种移植瘤模型,研究 WOG 联合化疗药物在体内的作用。
WOG、CDDP 和 PTX 呈剂量依赖性抑制 BGC-823、MGC-803、MKN-45 和 HGC-27 胃癌细胞的生长。WOG 联合 CDDP 或 PTX 协同抑制四种胃癌细胞系的生长。在 BGC-823、MGC-803、HGC-27 和 MKN-45 细胞系中,当 Fa 值<0.45、<0.90、<0.85 和<0.60 时,WOG 与 PTX 之间表现出协同作用。而当 Fa 值>0、>0、>0.65 和>0.10 时,WOG 与 CDDP 具有协同抑制作用。从肿瘤异种移植的体内实验结果来看,WOG 与低剂量 PTX 联合应用的效果优于单独用药。联合组、WOG 组和低剂量 PTX 组的肿瘤重量抑制率分别为 61.58%、20.29%和 22.28%。值得注意的是,WOG 联合 CDDP 表现出很高的毒性。
在胃癌细胞和肿瘤异种移植中,WOG 与低剂量 PTX 联合应用具有协同抑制生长的作用。这些发现为设计临床试验以测试 WOG 与低剂量 PTX 联合用于人类胃癌提供了依据。